Lead party: British International Investment (BII), Development Partners International (DPI) (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Egypt, Morocco
Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Equity · Deal amount: US$200m · Fund: African Development Partners III (ADP III)
Lead investor/buyer: British International Investment (BII), Development Partners International (DPI) · Investors/buyers: Proparco, Deutsche Investitions-und Entwicklungsgesellschaft (DEG), Netherlands Development Finance Company (FMO), Development Partners International (DPI), British International Investment (BII)
Legal advisers: not identified in the source record.
Source: announced 9 March 2022. Original announcement: proparco.fr.


